JP7169267B2 - 重症筋無力症を診断および治療するためのペプチドおよびその使用 - Google Patents

重症筋無力症を診断および治療するためのペプチドおよびその使用 Download PDF

Info

Publication number
JP7169267B2
JP7169267B2 JP2019513015A JP2019513015A JP7169267B2 JP 7169267 B2 JP7169267 B2 JP 7169267B2 JP 2019513015 A JP2019513015 A JP 2019513015A JP 2019513015 A JP2019513015 A JP 2019513015A JP 7169267 B2 JP7169267 B2 JP 7169267B2
Authority
JP
Japan
Prior art keywords
peptide
peptides
subject
seq
mir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019513015A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531716A5 (https=
JP2019531716A (ja
Inventor
ロバート エイチ． フェアクラフ
ヴ ビー． チン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2019531716A publication Critical patent/JP2019531716A/ja
Publication of JP2019531716A5 publication Critical patent/JP2019531716A5/ja
Application granted granted Critical
Publication of JP7169267B2 publication Critical patent/JP7169267B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
JP2019513015A 2016-09-08 2017-09-07 重症筋無力症を診断および治療するためのペプチドおよびその使用 Active JP7169267B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662384896P 2016-09-08 2016-09-08
US62/384,896 2016-09-08
PCT/US2017/050521 WO2018049053A2 (en) 2016-09-08 2017-09-07 Peptides and uses thereof for diagnosing and treating myasthenia gravis

Publications (3)

Publication Number Publication Date
JP2019531716A JP2019531716A (ja) 2019-11-07
JP2019531716A5 JP2019531716A5 (https=) 2020-10-08
JP7169267B2 true JP7169267B2 (ja) 2022-11-10

Family

ID=61562129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019513015A Active JP7169267B2 (ja) 2016-09-08 2017-09-07 重症筋無力症を診断および治療するためのペプチドおよびその使用

Country Status (8)

Country Link
US (1) US11422132B2 (https=)
EP (1) EP3512873B1 (https=)
JP (1) JP7169267B2 (https=)
KR (1) KR102501179B1 (https=)
CN (1) CN109996812A (https=)
AU (1) AU2017322312B2 (https=)
CA (1) CA3036130A1 (https=)
WO (1) WO2018049053A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7169267B2 (ja) 2016-09-08 2022-11-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 重症筋無力症を診断および治療するためのペプチドおよびその使用
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
CN121204097A (zh) * 2019-05-13 2025-12-26 宾夕法尼亚大学董事会 乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法
US12606631B2 (en) 2020-05-20 2026-04-21 Remd Biotherapeutics Inc Antibodies which bind human endothelin receptor a (ETAR)
CN112029880B (zh) * 2020-09-15 2023-04-28 石家庄市人民医院(石家庄市第一医院、石家庄市肿瘤医院、河北省重症肌无力医院、石家庄市心血管病医院) 用于重症肌无力的检测的微生物及应用
EP4217401A1 (en) 2020-09-24 2023-08-02 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509045A (ja) 1999-09-15 2003-03-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ニコチン性アセチルコリン受容体：アルファ１０サブユニット
JP2007183176A (ja) 2006-01-06 2007-07-19 Ind Technol Res Inst 重症筋無力症の診断方法およびそのキット
JP2011032188A (ja) 2009-07-30 2011-02-17 Nihon Pharmaceutical Co Ltd 融合蛋白質

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3391831B2 (ja) * 1993-01-13 2003-03-31 株式会社クラレ 環状ペプチド
US20020081652A1 (en) * 1997-05-07 2002-06-27 Sara Fuchs Recombinant fragments of the human acetylcholine receptor and their use for treatment of myasthenia gravis
HUP0301111A3 (en) * 2000-03-31 2004-08-30 Corixa Corp Seattle Pharmaceutical compositions containing potential immunodominant acetylcholine receptor oligopeptides and their use
WO2010014723A1 (en) * 2008-07-29 2010-02-04 The Board Of Regents Of The University Of Texas System Methods and composition related to acetylcholine receptor conjugates
JP7169267B2 (ja) 2016-09-08 2022-11-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 重症筋無力症を診断および治療するためのペプチドおよびその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509045A (ja) 1999-09-15 2003-03-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ニコチン性アセチルコリン受容体：アルファ１０サブユニット
JP2007183176A (ja) 2006-01-06 2007-07-19 Ind Technol Res Inst 重症筋無力症の診断方法およびそのキット
JP2011032188A (ja) 2009-07-30 2011-02-17 Nihon Pharmaceutical Co Ltd 融合蛋白質

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TRINH, V. B.，Therapeutic Peptide Mimics of the Acetylcholine Receptor Main Immunogenic Region for Treating Myasthenia Gravis，Ph.D. Thesis. University of California, Davis，2013年

Also Published As

Publication number Publication date
US11422132B2 (en) 2022-08-23
WO2018049053A2 (en) 2018-03-15
EP3512873B1 (en) 2023-11-01
KR20190045323A (ko) 2019-05-02
CN109996812A (zh) 2019-07-09
AU2017322312B2 (en) 2021-10-28
EP3512873A4 (en) 2020-03-18
EP3512873C0 (en) 2023-11-01
CA3036130A1 (en) 2018-03-15
WO2018049053A3 (en) 2018-05-17
EP3512873A2 (en) 2019-07-24
JP2019531716A (ja) 2019-11-07
AU2017322312A1 (en) 2019-03-28
KR102501179B1 (ko) 2023-02-16
US20200033338A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
JP7169267B2 (ja) 重症筋無力症を診断および治療するためのペプチドおよびその使用
CN115244077B (zh) 蛋白质治疗剂
JP6190113B2 (ja) オリゴマー特異アミロイドベータエピトープおよび抗体
ES2260756T3 (es) Proteina y peptidos alergenicos de caspa de perro y sus usos.
JP2010536356A (ja) β１−アドレナリン作動性レセプター抗体を阻害する変異体二重環化レセプターペプチド
US20210347824A1 (en) Antigenic peptides and uses thereof for diagnosing and treating autism
JP2000507232A (ja) 慢性関節リウマチの病理発生に必要な関節炎誘発性ペプチドに対して免疫防御を誘発するために有用なワクチン組成物と方法
JPH09502346A (ja) 自己免疫疾患に関連するプロトコールにおけるミエリン希突起神経膠細胞糖蛋白質およびそのペプチド部分の使用
CN106456700B (zh) 糖尿病治疗和预防的新靶标
JPH02479A (ja) ｓｎＲＮＰ−Ａ抗原及びそのフラグメント
JP2001512971A (ja) 癌および腫瘍随伴性神経症候群の診断および治療におけるｕｌｉｐの使用
US20120039919A1 (en) Diabetes diagnostic, prophylactic, and therapeutic compositions and methods
CN114729929B (zh) 诊断和治疗自闭症的抗原神经元特异性烯醇化酶肽
ES2305323T3 (es) Proteina citotoxica y utilizacion de la misma.
US20230181672A1 (en) Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
US20030215884A1 (en) Method of regenerating neurons
CN101161283A (zh) CMTM1-v17的新应用及其拮抗剂
EP4093775A1 (en) Anti-ide antibodies and uses of same
Popiolek Characterization of the D-amino acid oxidase interactome
WO2007049642A1 (ja) カプサイシン受容体の活性調節剤、及びそれを用いた医薬組成物
CN101041694A (zh) 血管生成素类似蛋白v及其制备方法,其多克隆抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190424

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200831

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220824

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221028

R150 Certificate of patent or registration of utility model

Ref document number: 7169267

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250